Delayed preattentional functioning in early psychosis patients with cannabis use

Psychopharmacology

Volumn 222, Issue 3, 2012, Pages 507-518

  Pesa, Nicole ^a,b   Hermens, Daniel F ^b   Battisti, Robert A ^b   Kaur, Manreena ^b   Hickie, Ian B ^b   Solowij, Nadia ^a,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Cannabis; Marijuana; Mismatch negativity; MMN; P3a; Psychosis

Indexed keywords

CANNABIS;

ADULT; ARTICLE; ATTENTION; BIPOLAR DISORDER; CANNABIS SMOKING; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRINKING BEHAVIOR; EDUCATIONAL STATUS; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; LATENT PERIOD; MAJOR DEPRESSION; MALE; MISMATCH NEGATIVITY; NEUROPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ATTENTION; COGNITION; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PSYCHOTIC DISORDERS;

EID: 84864442091     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2676-2     Document Type: Article

References (87)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th. ed., rev., DSM-IV-TR). Washington, DC: Author
2. Arseneault L, Cannon M, Witton J, Murray R (2004) Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry 184:110-117
3. Atkinson RJ, Michie PT, Schall U (2012) Duration mismatch negativity and P3a in first episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry 71:98-104
4. Babor TF, de la Fuente JR, Saunders J, Grant M (1992) AUDIT. The alcohol use disorders identification test. Guidelines for use in primary health care. World Health Organization, Geneva
5. Battisti RA, Roodenrys S, Johnstone SJ, Pesa N, Hermens DF, Solowij N (2010a) Chronic cannabis users show altered neurophysiological functioning on stroop task conflict resolution. Psychopharmacolol (Berl) 212:613-624
6. Battisti RA, Roodenrys S, Johnstone SJ, Respondek C, Hermens DF, Solowij N (2010b) Chronic use of cannabis and poor neural efficiency in verbal memory ability. Psychopharmacol (Berl) 209:319-330
7. Beauchamp CM, Stelmack RM (2006) The chronometry of mental ability: An event-related potential analysis of an auditory oddball discrimination task. Intelligence 34:571-586
8. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML, Giampietro V, BrammerM, Zuardi AW, Atakan Z,McGuire PK (2012) Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69:27-36
9. Bodatsch M, Ruhrmann S, Wagner M, Müller R, Schultze-Lutter F, Frommann I, Brinkmeyer J, Gaebel W, Maier W, Klosterkötter J, Brockhaus-Dumke A (2011) Prediction of psychosis by mismatch negativity. Biol Psychiatry 69:959-966
10. Braff DL, Light GA (2007) One year stability of mismatch negativity in schizophrenia patients. Schizophr Bull 33:401
11. Brockhaus-Dumke A, Tendolkar I, Pukrop R, Schultze-Lutter F, Klösterkotter J, Ruhrmann S (2005) Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr Res 73:297-310
12. Chitty KM, Kaur M, Lagopoulos J, Hickie IB, Hermens DF (2011) Alcohol use and mismatch negativity in young subjects with psychotic disorder. Neuroreport 22:918-922
13. de la Serna E, Mayoral M, Baeza I, Arango C, Andres P, Bombin I, Gonzalez C, Rapado M, Robles O, Rodriguez-Sanchez JM, Zabala A, Castro-Fornieles J (2010) Cognitive functioning in children and adolescents in their first episode of psychosis: Differences between previous cannabis users and nonusers. J Nerv Ment Dis 198:159-162
14. Di Forti M, Morrison PD, Butt A, Murray RM (2007) Cannabis use and psychiatric and cogitive disorders: The chicken or the egg? Curr Opin Psychiatr 20:228-234
15. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) δ9- tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594-608
16. Duncan CC, Barry RJ, Connolly JF, Fischer C, Michie PT, Näätänen R, Polich J, Reinvang I, Petten CV (2009) Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clin Neurophysiol 120:1883-1908
17. Fan N, Yang H, Zhang J, Chen C (2010) Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo δ9-THC exposure-impaired hippocampal synaptic plasticity. J Neurochem 112:691-702
18. Frodl-Bauch T, Gallinat J, Meisenzahl EM, Möller HJ, Hegerl U (1999) P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry 45:116-126
19. Goldman HH, Skodol AE, Lave TR (1992) Revising axis V for DSM-IV: A review of measures of social functioning. Am J Psychiatry 149:1148-56
20. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS (2004) First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res 66:125-135
21. Halgren E, Marinkovic K, Chauvel P (1998) Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol 106:156-164
22. HamiltonM(1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-96
23. Hampson AJ, Bornheim LM, Scanziani M, Yost S, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671-676
24. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10:40-68
25. Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB (2009) Amphetamine psychosis: A model for studying the onset and course of psychosis. MJA 190:S22-25
26. Hermens DF,Ward PB, Hodge MAR, Kaur M, Naismith SL, Hickie IB (2010) Impaired MMN/P3a complex in first episode psychosis: Cognitive and psychosocial associations. Prog Neuropsychopharmacol Biol Psychiatry 34:822-829
27. Hirayasu Y, Asato N, Ohta H, Hokama H, Arakaki H, Ogura C (1998) Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biol Psychiatry 43:244-253
28. Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwutikarn J, de Lacerda RB, Ling W, Marsden J, Monteiro M, Nhiwatiwa S, Pal H, Poznyak V, Simon S (2008) Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction 103:1039-1047
29. Inami R, Kirino E, Inoue R, Suzuki T, Arai H (2007) Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Neuropsychobiology 56:64-72
30. Jahshan C, Cadenhead KS, Braff DL, Light GA (2009) Duration mismatch negativity in prodromal and first-episode schizophrenia. Schizophr Bull 35:47
31. Jahshan C, Cadenhead KS, Rissling AS, Kirihara K, Braff DL, Light GA (2012) Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med 42:85-97
32. Javitt DC, Steinschneider M, Schroeder CE, Arezzott JC (1996) Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: Implications for schizophrenia. Proc Natl Acad Sci USA 93:11962-11967
33. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M (2008) Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev: Drug Discov 7:68-83
34. Jockers-Scherübl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gómez-Carrillo de Castro A, Kühl K-P (2007) Cannabis induces different cognitive changes in schizophrenic patients and healthy controls. ProgNeuropsychopharmacol Biol Psychiatry 31:1054-1063
35. Juckel G, Roserb P, Nadulskic T, Stadelmann AM, Gallinat J (2007) Acute effects of δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97:109-117
36. Kano M, Ohno-shosaku T, Hashimotodani Y, Uchigashima M,Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380
37. Kaur M, Battisti RA, Ward PB, Ahmed A, Hickie IB, Hermens DF (2011) MMN/P3a deficits in first episode psychosis: Comparing schizophrenia-spectrum and affective-spectrum subgroups. Schizophr Res 130:203-9
38. Kaur M, Battisti RA, Lagopoulos J, Ward PB, Hickie IB, Hermens DF (In press). Neurophysiological biomarkers support bipolarspectrum within psychosis cluster. JPN, accepted 20/12/11
39. Kumra S, Thaden E, DeThomas C, Kranzler H (2005) Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and Schizoaffective disorder. Schizophr Res 73:369-371
40. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr Res 94:29-36
41. Linszen DH, Nieman DH (2004) Cannabis use adversely affects P300 event-related potential latency in recent-onset schizophrenia. Schizophr Res 67:218-219
42. Liraud F, Verdoux H (2002) Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 28:160-168
43. Liu Q, Bhat M, Bowen WD, Cheng JG (2009) Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J Pharmacol Exp Ther 331:1062-70
44. Mager R, Stefani O, Angehrn I, Mueller-Spahn F, Bekiaris E,Wiederhold B, Sulzenbacher H, Bullinger A (2005) Neurophysiological age differences during task-performance in a stereoscopic virtual environment. Appl Psychophysiol Biofeedback 30:233-238
45. Mathalon DH, Ford JM, Pfefferbaum A (2000) Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol Psychiatry 47:434-449
46. McConchie M, Hides L, Proffitt TM, Kerr M, Markulev C, Wood S, Lubman DI, McGorry PD, Berger GE (2006) Cannabis, amphetamines and first-episode psychosis: Prevalence and relationship to outcome. Schizophr Res 81:S305
47. Michie PT (2001) What has MMN revealed about the auditory system in schizophrenia? Int J Psychophysiol 42:177-94
48. Michie PT, Innes-Brown H, Todd J, Jablensky AV (2002) Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biol Psychiatry 52:749-758
49. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370:319-28
50. Morgan CJA, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study. Br Psychiatry 197:285-290
51. Münte TF, Urbach TP, Düzel E, Kutas M (2000) Event-related brain potentials in the study of human cognition and neuropsychology. In: Boller F, Grafman J, Rizzolatti G (eds) Handbook of neuropsychology: Volume 1. Elsevier Science, Amsterdam, pp 139-236
52. Näätänen R (1990) The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav Brain Sci 13:201-88
53. Näätänen R (1992) Attention and brain function. Lawrence Erlbaum Associates, New Jersey
54. Näätänen R, Kahkonen S (2009) Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: A review. Int J Neuropsychopharmcol 12:125-135
55. Nicholson IR, Chapman JE, Neufeld RWJ (1995) Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 17:177-185
56. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
57. Pencer A, Addington J (2003) Substance use and cognition in early psychosis. J Psychiatry Neurosci 28:48-54
58. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br J Pharmacol 153:199-215
59. Petersen L, Nordentoft M, Bertelsen M, Thorup A (2007) Does cannabis abuse determine outcome among patients with first episode psychosis. Results from the opus-trial. Schizophr Bull 33:453-453
60. Polich J (2007) Updating P300: An integrative theory of P3a and P3b. Clin Neurophysiol 118:2128-2148
61. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12:1152-1160
62. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol (Oxf) 23:266-277
63. Rentzsch J, Buntebart E, Stadelmeier A, Gallinat J, Jockers-Scherübl MC (2011) Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res 130:222-227
64. Roser P, Della B, Norra C, Uhl I, Brüne M, Juckel G (2010) Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci 60:491-498
65. Roser P, Haussleiter IS, Chong HJ, Maier C, Kawohl W, Norra C, Juckel G (2011) Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacol (Berl) 218:611-620
66. Salisbury DF, Shenton ME, Sherwood AR, Fischer IA, Yurgelun-Todd DA, Tohen M, McCarley RW (1998) First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry 55:173-180
67. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW (2007) Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 64:521-529
68. Scott E, Naismith S, Whitwell B, Hamilton B, Chudleigh C, Hickie I (2009) Delivering youth-specific mental health services: The advantages of a collaborative, multi-disciplinary system. Australas Psychiatry 17:189-194
69. Semlitsch HV, Anderer P, Schuster P, Presslich O (1986) A solution for reliable and valid reduction of ocular artifacts, applied to the P300. Psychophysiology 23:695-703
70. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N (1991) Mismatch negativity: An index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 30:1059-1062
71. Solowij N (1998) Cannabis and cognitive functioning. Cambridge University Press, Cambridge
72. Solowij N, Michie P (2007) Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30-52
73. Solowij N, Pesa N (2010) Cognitive abnormalities and cannabis use. Rev Bras Psiquiatr 32:531-40
74. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123-1131
75. Stirling J, Lewis S, Hopkins R, White C (2005) Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 75:135-137
76. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Näätä nen R (2008) Deviant matters: Duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 63:58-64
77. Todd J, Michie PT, Schall U, Ward PB, Catts SV (2011) Mismatch negativity (MMN) reduction in schizophrenia-impaired prediction-error generation, estimation or salience? Int J Psychophysiol. doi:10.1016/j.ijpsycho.2011.10.003
78. Turetsky BI, Colbath EA, Gur RE (1998) P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol Psychiatry 43:84-96
79. Turetsky BI, Bilker WB, Siegel SJ, Kohler CG, Gur RE (2009) Profile of auditory information-processing deficits in schizophrenia. Psychiatry Res 165:27-37
80. Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: A meta-analysis. Schizophr Res 76:1-23
81. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual contextdependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139-1147
82. Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, Stassen H (2003) How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 53:1120-1131
83. Valkonen-Korhonen M, Purhonena M, Tarkkab IM, Sipila P, Partanenc J, Karhuc J, Lehtonen J (2003) Altered auditory processing in acutely psychotic never-medicated first-episode patients. Brain Res Cogn Brain Res 17:747-758
84. Wechsler D (2002) Wechsler test of adult reading. Psychological Corporation, San Antonio
85. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI (2008) Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65:694-701
86. Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton S, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012) The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 38:316-330
87. Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimaraes FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421-429